Chemogenetic characterization through in vitro evolution combined with whole genome analysis is a powerful tool to discover novel antimalarial drug targets and identify drug resistance genes. Our comprehensive genome analysis of 262 Plasmodium falciparum parasites treated with 37 diverse compounds reveals how the parasite evolves to evade the action of small molecule growth inhibitors. This detailed data set revealed 159 gene amplifications and 148 nonsynonymous changes in 83 genes which developed during resistance acquisition. Using a new algorithm, we show that gene amplifications contribute to 1/3 of drug resistance acquisition events. In addition to confirming known multidrug resistance mechanisms, we discovered novel multidrug resistance genes. Furthermore, we identified promising new drug target-inhibitor pairs to advance the malaria elimination campaign, including: thymidylate synthase and a benzoquinazolinone, farnesyltransferase and a pyrimidinedione, and a dipeptidylpeptidase and an arylurea. This deep exploration of the P. falciparum resistome and drug-able genome will guide future drug discovery and structural biology efforts, while also advancing our understanding of resistance mechanisms of the deadliest malaria parasite.
Main Text:
Malaria has a disproportionately negative impact on human health because its causal protozoan parasites are adept at changing their genomes to evade antimalarial drugs and the human immune system. A human infection may contain upwards of to 10 12 asexual blood stage parasites.
Thus, even with a relatively slow random parasite mutation rate (~10 -9 ), within a few cycles of replication each base in the P. falciparum genome can acquire a random genetic change that may render at least one parasite resistant to the activity of a small molecule or a human-encoded antibody. The recent evolution of artemisinin-resistant parasites in Southeast Asia now threatens a life-saving treatment in addition to malaria control efforts(1).
Although this rapid evolution impedes our ability to control the disease, it can also be used to our advantage since in vitro evolution in the presence of known antimalarials followed by whole-genome sequencing of resistant clones can be used to discover important mediators of drug resistance. For example, the kelch13 allele that is associated with artemisinin resistance was first identified in the genome sequence of an in vitro cultured P. falciparum parasite line exposed to sublethal concentrations of dihydroartemisinin in the laboratory (2) . This method of resistance evolution can also reveal new antimalarial drug targets (3) . Unlike drug targets that are validated using genetic knockdown methods, these chemically validated drug targets are more valuable as it is already clear that their activity can be inhibited in cultured parasites by a small molecule. Furthermore, the inhibitor provides a tool for crystallization and chemical genetic studies. Some of the important new drug targets discovered with this method include lysyl tRNA synthetase (pfkrs1)(4), P-type ATPase 4 (pfatp4) (5, 6) , phosphatidylinositol-4-kinase (7, 8) , phenylalanine tRNA synthetase (7) , isoleucine tRNA synthetase (9) , eukaryotic elongation factor 2 (10) , and the polyadenylation specificity factor subunit 3 (11) .
Most studies using this method to date have focused on single gene mutations in response to single compounds even though, in many cases, additional allelic changes have been noted in P. falciparum clones during the acquisition of compound resistance. Here, we systematically study patterns of P. falciparum genome evolution by analyzing the sequences of clones resistant to diverse compounds with antimalarial activity across the P. falciparum lifecycle, in order to comprehensively assess the parasite's evolutionary development of drug resistance and identify novel antimalarial targets.
Results

Next-generation sequencing shows neutral selection for allelic changes in subtelomeric regions and strong positive selection for variants in the core genome
To thoroughly investigate the genomic evolutionary response to treatment with small molecules, we assembled a collection of isogenic P. falciparum clones that had acquired resistance to a range of different small-molecule growth inhibitors. Of the 37 different small molecules used during in vitro resistance evolution (Table S1 ), 26 compounds were hits from P. falciparum phenotypic screens (12) (13) (14) (15) . Others were the result of medicinal chemistry optimization: the spiroindolone NITD678 (5) , and the imidazolopiperazines GNF179, GNF452, and GNF707 (16) , which are similar to KAE609 and KAF156, respectively. The latter two compounds are novel antimalarials that are currently in clinical trials (17, 18) . Two compounds, atovaquone and primaquine, are licensed antimalarials. Although a few compounds were similar to one another, such as three carbazoles (MMV019017, MMV009063 and MMV665882), and the imidazolopiperazines (GNF707, GNF452 and GNF179), most possessed a distinct variety of functional groups and heterocyclic substructures. Some compounds showed activity across the parasite lifecycle (Table S1 , Table S2) ).
Although the phenotypes of some clones had been previously described (19) , other clones, including those resistant to primaquine and several clones resistant to GNF179, were evolved specificially for this study over a period of 3-6 months ( Figure S1 ) using a slow ramp-up method of compound exposure. The parasite clones exhibited varying levels of resistance relative to their isogenic parent clones (lower and upper quartile of the half maximal effective concentration (EC 50 ) fold shift of resistant clones was 2.8 and 37.2, respectively (Table S3) ) and in all cases, demonstrated genetically stable resistance. Genomic DNA was available from an average of 6.45 (median = 5) independently-derived clones for each compound.
To identify the genetic basis of drug resistance, 204 clones (including resistant clones and sensitive isogenic parent clones) were resequenced using the paired-end read method of whole genome sequencing. We included 58 published genomic sequences for clones resistant to 12 compounds, including cladosporin(4), atovaquone (20) , and GNF179 (21) . Alignment to the P.
falciparum reference genome showed that on average, there was 80.3X coverage of the 23.3 million base pair genome with 85.3% of bases covered by 20 or more reads (Table S3 ). Nonreference alleles present in each evolved group of clones and absent in the isogenic parent clone were identified. In total, we discovered 1,277 single nucleotide variants (SNVs) and 668 small insertions or deletions (indels) that arose in the 262 whole genome sequences during resistance acquisition (Figure1A, Table 1 , Table S4 ).
Because sequencing might identify false-positive or false-negative alleles, we validated our small variant detection pipeline using several tests. Previous whole-genome analyses of P. falciparum using microarrays and sequencing (20, 22) showed that during long-term in vitro growth, genes encoding proteins involved in antigenic variation (such as var and rifin genes), which are usually located in the subtelomeric regions, rapidly acquire mutations. Thus, we hypothesized that we would find a similar pattern for small variants in our data set. Indeed, 1,107 of these variants were located in the 6% of the genome that encodes proteins involved in antigenic variation, referred to as the non-core genome (Table 1) . We further predicted that if the mutations in the core genome conferred a selective advantage, then we would find an enrichment of nonsynonymous coding changes. As predicted, the ratio of nonsynonymous to synonymous changes in the noncore region was ~2:1 (216:128) indicating near neutral selection and further confirming the high mutabilility of these genes in the absence of selection. In contrast, the ratio of nonsynonymous coding to synonymous coding alleles in the 23 Mb core genome was 7:1 (148:21) indicating an uneven distribution (p = 7.7E-10) and strong positive selection. In the core genome (containing 838 variants), there were only 148 nonsynonymous changes (Table S5) found in only 83 genes (Table S6) , with less than one nonsynonymous change per evolved clone ( Table   2 ).
We also predicted that this set of 83 genes would be enriched for genes with annotated roles in drug resistance and that known mutations would be detected in the appropriate compoundspecific groups of clones. In fact, gene ontology enrichment testing did reveal that the set of 83 genes was statistically enriched for genes with a response to drug gene ontology biological process designation (GO:0042493: p=5.78E-07, Table S7 ). To the best of our knowledge, there were no false negatives: known variants in P-type cation-transporter ATPase4 (pfatp4;PF3D7_1211900) (5, 23) in NITD678-resistant clones, cytochrome bc1 (pfcytb;mal_mito_3) (20) in atovaquone-resistant clones, acetyl-coA transporter (pfact;PF3D7_1036800) in GNF179-resistant clones, cyclic amine resistance locus (pfcarl;PF3D7_0321900)(24) in GNF179, GNF452, and GNF707-resistant clones, and multidrug resistant protein (pfmdr1;PF3D7_0523000) in ACT-451840-resistant clones (25) were all detected (Table S6 ), further validating our data set.
Most drug-resistant clones acquire copy number variants in addition to SNVs
Copy number variants (CNVs) also contribute to drug resistance in P. falciparum (26) (27) (28) .
For example, amplification of pfmdr1 confers multidrug resistance, including resistance to mefloquine and lumefantrine (29) . However, traditional sequencing read depth-based methods of CNV detection are more problematic in P. falciparum since the genome is extremely AT-rich (~81%), which leads to uneven genome coverage (30) . Thus, we established an automated pipeline for their detection using normalized coverage across our entire data set (see methods). Briefly, average read depth was computed for coding regions only, since intergenic regions of P.
falciparum are 90-95% AT-rich with AT-repeat segments (31) and thus exhibit reduced alignment confidence. The read coverage data were normalized in three groups depending on the genetic background (3D7, Dd2 or 7G8), allowing the identification of increased read coverage in regions known to be amplified in certain backgrounds (e.g. the pfmdr1 region amplifications in Dd2). Sets of 2 or more contiguous genes showing ~2.0 X change over the mean were identified. Potential amplified regions were further filtered to yield 159 high-confidence CNVs (core genome, mean average coverage per gene set > ~3.0X over mean coverage and Benjamini-Hochberg corrected p <0.001) ( Table 3 , Table S8 ). Altogether, 159 CNVs were observed in P. falciparum clones resistant to 27 of the 37 compounds ( Table 3 , Table S9 ). CNVs were found primarily on chromosomes 1, 3, 5, and 12 with an average size of ~65 kb ( Figure 1 , Table 3 ). Of note, 76 core genome deletions were also identified (Table S10 ), but most of these were small (< 5 genes), located in subtelomeric regions, and seemed unrelated to the acquisition of drug resistance. For example, some 3D7 clones harbored known deletions of the left arm of chromosome 2, which lacks known drug susceptibility modulators.
To validate our CNV detection algorithm, we performed additional tests to assess its robustness. We analyzed randomized, permuted average read coverage data and identified only ~8 CNVs fulfilling these criteria. To assess our false negative rate, we next confirmed that we could detect known CNVs previously detected by microarray analysis, including those that span lysyl tRNA synthetase (pfkrs1;PF3D7_1350100) in three cladosporin-resistant clones(4) (p = 1.89E-40, 2.29E-23 and 1.28E-12 for the three clones, respectively), and the amplification event encompassing the multidrug resistance protein 1 locus (pfmrp1;PF3D7_0112200) in the atovaquone-resistant clone R5a(20)(p = 4.09E-33). The known amplification surrounding pfatp4
in NITD678-resistant clones(5) was not detected, likely because this clone was sequenced with an older, 60 base pair (bp) read length technology and was therefore not comparable to the rest of the set (although the amplification could be visually detected when compared to other samples sequenced with 60 bp reads). Finally, we used orthologous methods to confirm the CNVs. Many
CNVs could be visually confirmed by identifying paired-end reads from sequencing library fragments that spanned the CNV boundaries in the Integrative Genomics Viewer(32, 33) (IGV) and by PCR over the boundaries as previously described ( Figure 1B , Figure 1C , Figure S2 ) (34) .
We found that CNV read coverage correlated with EC 50 shift in resistant clones when no other resistance-conferring mutations were present, such as the pfmdr1 amplification in clones resistant to compound MMV665789 ( Figure 1B ).
Resistance mechanisms are reproducible and structure dependent
As a final test of our dataset we predicted that treating parasites with similar chemical structures would yield reproducible genomic changes. Clustering based on compound similarity did show parasites acquired similar resistance alleles when treated with compounds that are structurally similar ( Figure 2 ). For example, independent clones resistant to imidazolopiperazines (GNF452, GNF707, GNF179) and the closely related compound, MMV07564, acquired mutations resulting in coding changes in the cyclic amine resistance locus (pfcarl;PF3D7_0321900). In another example, amplification of the pfmdr1 region was observed in all 3D7 clones that acquired resistance to three closely related carbazoles: MMV009063, MMV019017, and MMV665882 (Table S8 , Figure S2 ).
The P. falciparum resistome
Our dataset of CNVs and SNVs revealed 35 genes with two or more types of evidence suggesting a role as a drug resistance determinant or as a drug target ( Figure 2 ). Evidence included:
being within an amplification event and bearing SNVs, the presence of two different alleles in the same gene for the same compound, or the same allele appearing in response to two different compounds. Mutations in pfmdr1 were discovered for 6 different compounds, confirming its known role in drug resistance. Notably, a highly likely resistance mechanism or target gene was discovered for each compound examined. Below, we discuss some of the genes with the strongest evidence.
Discovery of new alleles in known drug resistance genes
Genetic detection of alleles associated with antimalarial resistance is the primary method of tracking resistance in clinical samples, because in vitro phenotypic susceptibility testing is difficult and costly in malaria parasites. Analysis of the mutations present in our large set of resistant P. falciparum clones revealed both known and novel genes implicated in drug resistance.
In addition to known mutations mentioned above, we found new mutations in several well-known P. falciparum resistance mediators. For example, we found four new alleles in the gene encoding the P. falciparum chloroquine resistance transporter (pfcrt;PF3D7_0709000), including S65R, A138V, K76Q and S90N amino acid changes. Although one of the selection compounds, MMV006767, bears an aminoquinoline core similar to chloroquine, neither MMV011895 or MMV024114 do, providing evidence that PfCRT is a pleotropic transporter regulating drug levels in the digestive vacuole. We also found a novel F806L allele in pfmdr1 in MMV026596 resistant lines. Furthermore, strong amplification of the pfmdr1 region was observed in all 3D7 clones that had acquired resistance to MMV009063 (8 of 8 clones, average amplification 10X), MMV019017
(4 of 4 clones) and MMV665882 (5 of 5 clones) as well as MMV665789 (7 of 7 clones) (Table   S8 ). Subsequent testing showed that clones were now cross-resistant to mefloquine, consistent with pfmdr1 amplification ( Figure S3 ). A new nonsynonymous SNV was also discovered in studies. In our comprehensive data set, we observed that particular genes were mutated repeatedly in response to diverse compounds, indicating that they are more likely to be mediators of general drug resistance. One such candidate is the putative ABC transporter encoded by pfabcI3
(PF3D7_0319700) (35) . Compounds that selected for mutations in pfabcI3 (MMV020746, MMV023367, MMV024114, MMV029272 and MMV665939) are structurally diverse and some are active across the parasite lifecycle (19) . The predicted gene product acquired point mutations (L690I, R2180G, R2180P (two times), and Y2079C) during resistance selections and was central to 12 different chromosome 3 amplification events (Table 2, Figure 1C ). All three of the mutated amino acid residues are on loops between two transmembrane domains.
A novel class of potential resistance mediator in this study was a predicted amino acid transporter of the solute carrier family protein (SLC32 family) (pfaat1;PF3D7_0629500).
Orthologs of this conserved protein are responsible for the transport of amino acids in synaptic vesicles in humans (37) . Mutations in this gene were also found in loops between transmembrane domains and were associated with resistance to three diverse compounds: MMV007224 (-135I inframe insertion), MMV668399 (P380S, K238N, V185L), and MMV011895 ((F230L). This gene was found to be associated with levels of chloroquine resistance in P. falciparum in a genomewide association study (38) , and we found that the product of pfaat1 localizes to the P. falciparum digestive vacuole ( Figure S4 ). Thus, the amino transporter encoded by pfaat1 may play a role in efflux of multiple drugs from the digestive vacuole, similar to PfCRT.
Nonessential genes and drug activators
Because genes with stop-gained mutations are unlikely to encode critical drug targets, such genes likely play a role in compound detoxification. It was previously reported that the P.
falciparum Prodrug Activation and Resistance Esterase (pfpare;PF3D7_0709700), which is annotated as a lysophospholipase, provides resistance to MMV011438 and pepstatin butyl ester (39) . Another gene annotated as a lysophospholipase is PF3D7_0218600, which bears a FabD/lysophospholipase-like domain, and harbors frameshift mutations in two independent clones (MALDA-Primaquine-PQG10 and MALDA-Primaquine-PQA11) that acquired blood stage primaquine tolerance after 5 months of exposure ( Figure S1 ). This gene was not mutated in any of the other 261 clones and comprised two of the eight codon-changing core mutations (3 frameshift, 4 missense, and one stop-gained) in seven different primaquine-resistant clones.
Another amino acid transporter (pfaat2;PF3D7_1208400), was mutated in a clone (NMicro-GNF179-S2-3D7-2C) resistant to GNF179, an imidazopiperazine that is closely related to the clinical candidate KAF156 (17) . pfaat2 is predicted to contain 10 transmembrane domains and a pfam01490 amino acid transporter domain. The position 903 stop mutation was found in concert with a splice acceptor intronic mutation in the acetyl CoA transporter (pfact;PF3D7_1036800), a gene whose disruption confers resistance to imidazolopiperazines (40) .
CRISPR/Cas9 introduction of the pfaat2 L903 stop codon into GNF179-sensitive Dd2 parasites revealed that this mutation also conferred resistance to GNF179 on its own (EC 50 fold shift of 38fold compared to the sensitive parent clone) ( Figure S5 ).
Transcription factors
Several resistance mediators that we discovered are likely to play a role in the parasite's transcriptional response to drugs. Although there are no examples in P. falciparum, work in S.
cerevisiae and other microbes has shown that mutations in transcription factors can often result in multidrug resistance (41) . In our study, the most commonly mutated class of gene was the Apicomplexan AP2 transcription factor family (10 different variants observed in 5 different AP2 transcription factor-encoding genes as well as several potential intergenic promoter mutations). In plants, AP2 transcription factors are involved in the cellular response to stress(42) and in Plasmodium, they regulate a variety of developmental transitions including commitment to sexual development and sporogony (43, 44) . The most prominent AP2 transcription factor in our set was PF3D7_0613800, which appeared three times with three independent compounds (MMV665882, MMV665939 and MMV011438). In two cases, the same codon deletion (QMEGDNEMEGDNE197Q) was observed, and in one case there was a nonsynonymous codon change (Q197E) at the same position. In addition, a region on chromosome 10 that encompassed a gene encoding another AP2 transcription factor (pfap2tf-10;PF3D7_1007700) was amplified in 9 clones (Table 3 ). The amplification on chromosome 10 appeared in one primaquine-resistant clone (consisting of only 7 genes with an estimated 4 to 5 copies, p = 6.6E-5), as well in clones resistant to GNF179, MMV008148 or MMV011438. Variants in the chromosome 6 transcription factor (PF3D7_0613800) were associated with resistance to quinine in genome-wide association studies (45) . However, more work is needed to determine whether these changes are associated with multidrug resistance or are related to long term in vitro culturing.
The Forkhead-associated domain is a phosphopeptide recognition domain found in some kinases and transcription factors (46) . Mutations in an uncharacterized protein bearing this domain (pffhd, PF3D7_0909700) were found in all samples resistant to MMV668399 (p = 1E-18 using an accumulative binomial distribution). Mutations included a M1V start-lost mutation, a K392 stopgained mutation, L95R and G720E missense mutations, and a gene deletion (MALDA-MMV668399-2F2). Given that three of the mutations were predicted loss of function, we hypothesize that this is a gene that inhibits drug action. These same resistant clones also contained mutations in the amino acid transporter (pfaat1; PF3D7_0629500) described above, and the inorganic anion transporter (pfsulp;PF3D7_1471200) (see below).
New targets and compound-target inhibitor pairs
In addition to discovering new genes involved in drug resistance, another goal of this study was to identify novel antimalarial drug targets to fill the urgent need for alternative malaria treatments and advance the elimination campaign. In general, we considered mutations in genes encoding enzymes as potential drug target candidates, which was further supported if the mutated gene was compound-specific and docking and homology modeling showed mutations in the catalytic site. A previously reported example is the set of BRD1095-resistant clones, which bear four different amino acid position changes(7) located in the predicted active site of the alpha unit of the cytosolic phenylalanyl-tRNA synthetase.
Thymidylate synthase. One likely target-inhibitor pair is dihydrofolate reductasethymidylate synthase (pfdhfr-ts;PF3D7_0417200) and the benzoquinazolinone MMV027634.
Although dihydropyrimidine inhibitors of the bifunctional enzyme are well-known antimalarials (e.g. pyrimethamine), all target the dihydrofolate reductase portion of the dual-function protein.
We identified three different nonsynonymous mutations mapping to the thymidylate synthase portion of the bifunctional molecule in the MMV027634-resistant lines ( Figure 3A) . Mapping of the mutations onto a published thymidylate P. falciparum crystal structure (47) showed that each mutation flanks the 2'-deoxyuridylic acid (dUMP) binding site of the enzyme ( Figure 3A ).
Independent docking of MMV027634 provided evidence that both substrates occupy the thymidylate synthase active site with a calculated affinity of -8.9kcal/mol.
Farnesyltransferase. Farnesyltransferase (pfftb; PF3D7_1147500) represents another target gene, which acquired two different mutations in amino acid 515 (A515V, A515T) in three clones resistant to the pyrimidinedione MMV019066 ( Figure 3B ). Modeling shows that the mutation at amino acid 515 likely disrupts interactions between the thienopyrimidine and the farnesylation active site, resulting in a resistant phenotype. Previous work has shown mutations in the lipid substrate binding site of farnesyltransferase in tetrahydroquinoline-resistant parasites (48) .
Dipeptidyl aminopeptidase 1. Another potential target gene is dipeptidyl aminopeptidase 1 (DPAP1) (pfdpap1;PF3D7_1116700), which encodes an exopeptidase that localizes to the digestive vacuole and cleaves amino terminal dipeptides from proteins or oligopeptides (49) . Each parasite clone resistant to MMV029272, an arylurea, carried a mutation (L437S, L415P or N62H) in DPAP1. This gene is considered to be essential as it cannot be disrupted (50) . All resistant clones also contained amplifications that encompassed the ABC transporter (pfabcI3; PF3D7_0319700), highlighting how resistance mechanisms can be found along with targets ( Figure 1C ).
Aminophospholipid-transporting P-type ATPase. As was previously reported for cladosporin and lysyl tRNA synthase(4), gene amplification events can occur around drug targets.
We detected six CNVs in a genomic region on chromosome 12 that encompass a predicted aminophospholipid-transporting P-type ATPase (pfatpase2;PF3D7_1219600) ( Figure 1D , Table   2 ), previously named PfATP2. Tandem amplifications with approximate sizes of 8.7 kb, 29 kb, and 25 kb were found in MMV007224-resistant clones and amplifications of 102kb, 95kb and 38kb were found in MMV665852-resistant lines. The 8.7 kb amplification events encompassed only two genes, namely the transporter and a truncated var pseudogene (PF3D7_1219500),
indicating that the transporter is likely the target. This protein is closely related to PfATP4, an important antimalarial drug target. In the closely related rodent malaria parasite, P. berghei, this transporter was refractory to targeted gene deletion attempts, demonstrating its essentiality (51) .
MMV007224 and MMV665852 are structurally similar to one another and are both active against liver-stage parasites. S. cerevisiae orthologs of pfatp2 encode the Dnf1/Dnf2 aminophospholipid translocases (flippases), which maintain membrane lipid asymmetry at the plasma membrane and contribute to endocytosis (52) . In support of this activity, additional nonsynonymous variants in MMV007224-resistant lines were predicted to encode proteins involved in similar processes:
Sec24, a component of the coat protein complex II (COPII) that promotes vesicle budding from the endoplasmic reticulum (ER), and Yip1, a protein required for fusion of these ER-derived vesicles with the Golgi. Of note, MMV665852 is a triclocarban, an antibacterial agent whose proposed mechanism is hypothesized to be inhibition of fatty acid synthesis, similar to triclosan, which was proposed to inhibit lipid an membrane function in Plasmodium (53, 54) .
Finally, in some cases, whether a gene encodes a promising target or a resistance gene may not be obvious. For example, PF3D7_0107500 is annotated as a lipid-sterol symporter in the Resistance-Nodulation-Division (RND) transporter family. We detected 5 different SNVs in this gene in clones resistant to MMV028038, MMV019662 and MMV009108, in addition to 12 amplification events surrounding this gene in clones resistant to MMV028038 and MMV019662.
Additional heterozygous SNVs were found in this gene in the MMV019662-resistant clones with chromosome 1 amplification events (Table S11 ). MMV028038 and MMV019662 both have an amide bond, whereas MMV009108 is very different. RND family transporters are wellcharacterized in Gram-negative bacteria, where they are involved in extruding toxins, exporting virulence determinants, and maintaining overall homeostasis (55, 56) . While specific pumps in this family have been associated with multidrug resistance in bacteria (57) , it is currently unclear what specific function the transporter encoded by PF3D7_0107500 has in P. falciparum. In addition, three different SNVs (D520Y, K615N, and I596M) were detected in an annotated inorganic anion transporter (pfsulp;PF3D7_1471200) in clones resistant to the pyrimidine MMV668399. The probability of randomly observing the same gene three times in 6 selections is extremely low (p = 4.03E-11). PF3D7_1471200 encodes a protein of the SLC26 membrane protein family(58) with 11 transmembrane domains. Homology models with a fumurate transporter (59) showed that all mutations were located in the STAS domain, a cytoplasmic extension that in some species plays a role in signal transduction.
Discussion and Conclusions
Our study represents one of the most comprehensive and controlled studies of antimalarial drug resistance acquisition by P. falciparum to date. Prior studies examining the parasite's genetic response during drug resistance development have evaluated the response to known antimalarials only (38, 45, 60, 61) , or have focused on coding mutations in one target gene in reponse to a single compound class (4) (5) (6) (7) (8) (9) (10) 39) . It is likely that the genes that are identified here will prove important to both clinical studies and the process of drug development.
One of the most remarkable findings in this data set is the large enrichment of mutations under positive selection. We focused here on genes for which there were multiple lines of supporting evidence across our study, however it is likely that there are other important genes in the set that were not discussed. Excluding genes contained within CNVs, the list of 57 singleton genes with nonsynonymous mutations includes ones encoding potential drug-able targets, such as GTPases, mRNA decapping enzymes, components of V-type ATPase complexes, kinases, and ubiquitin ligases (Table S5 ). Although some of these nonsynonymous changes could have arisen by chance, some are plausible. For example, although resistance to ACT-451840 is known to be conferred by mutations in pfmdr1 (62) , a mutation in the gene encoding a putative replication factor C subunit 4 (PF3D7_1241700) that results in a S42T amino acid change near the ATP binding pocket was found in two independent ACT-451840-resistant clones(62) ( Figure S6 ). Replication factor C subunit 4 is the subunit ATPase in the clamp-loading DNA polymerase complex and would be expected to be essential and a good drug target. Modeling shows that ACT-451840 could bind between subunits 1 and 4 of replication factor C, potentially disrupting ATPγ ingress. Our findings also highlight the large number of uncharacterized genes in the P. falciparum genome and the need for further functional annotation.
Not all mutations discovered in this study will necessarily confer resistance-they may compensate, specifically or nonspecifically, for a fitness loss caused by a resistance conferring mutation, or they may be associated with adaptation to long-term in vitro culture. Genome editing or creating recombinant lines may be used to confirm that alleles provide resistance (5, 7, 8, 11, 25, 40, 63) . On the other hand, given the multigenic nature of resistance, it could be difficult to fully recreate a resistance phenotype. For example, although evolved nonsynonymous changes in phenylalanine tRNA synthetase suggested that this was the likely target of BRD1095 (7), biochemical assays were ultimately needed to provide proof that this inhibitor blocks protein biosynthesis. We show here that the nonsynonymous changes that emerged in phenylalanine tRNA ligase were accompanied by copy number changes at unrelated sites, potentially explaining why genome editing attempts were unsuccessful.
Although dogma suggests that silent mutations do not affect protein function, the low frequency at which they were found in the set suggested a possible role for some. After excluding genes in the non-core genome, we identified only 21 silent mutations, many of which were in plausible drug targets, including protein kinase 4, Ark3 kinase, cytochrome c oxidase 3, a histonelysine N-methyltransferase, a putative serine threonine protein kinase, a DNA helicase and an 18S ribosomal RNA. Several of the genes with silent mutations were highly expressed, including cytochrome c oxidase subunit 3 for which the mutation creates a rare codon from a frequently used one (acA (23.8% usage for threonine) to acG (3.6%)). Interestingly, it has been shown that silent mutations in human mdr1 can confer resistance to cancer drugs by altering protein folding (64) .
Further work will be needed to establish whether these play a role in drug resistance or adaptation to long-term growth in P. falciparum. Similarly, intergenic and intronic mutations were also common. While in most cases resistance was explained by the presence of nonsynonymous coding mutations in the target or in resistance genes, intergenic mutations were also common. Likewise, in our dataset intron variants were much more likely to be found in the core genome than in subtelomeric regions (64:5), suggesting a possible functional role for this abundant class of mutations.
Finally, it is likely that among the genes we identified, several may contribute to clinical resistance at some level. Although the pharmacokinetics are different in humans compared to a tissue culture flask, we repeatedly rediscovered mutations in genes that are known to be important for clinical resistance. It is therefore likely likely that the new genes identified here are prime candidates for genes under selection in clinical isolates. Review of mutations in 3,247 P.
falciparum clinical isolates from the Malaria Genomic Epidemiology Network P. falciparum Community Project reveals that four genes that were identified in this study as mediators of resistance (the ABC transporter pfabcI3, the putative amino acid transporter pfaat2, the AP2 transcription factor pfap2tf-6b, and the farnesyltransferase, pfftb), have nonsynonymous to synonymous ratios greater than 2:1, providing evidence that they are likely under positive selection(65)( Table S12 ). Further research is required to define the potential role of these genes in clinical drug resistance. In addition, our data highlights the importance of CNVs in conferring multidrug resistance and suggests that high-coverage genome sequencing of clinical isolates will provide valuable information on selective pressures in the field.
It is notable that we were able to identify a likely target or resistance gene for every compound that we evolved resistance to using this method. The simple haploid genome and the lack of transcriptional feedback loops suggest that P. falciparum is a particularly good model for both target identification and resistome studies. Our characterization of the chemogenetic landscape of P. falciparum establishes a new paradigm to guide the design of small molecule inhibitors against deadly eukaryotic pathogens. MMV019066  11  11  3  3  3D7  MMV019662  92  78  6  15  3D7  MMV019719  6  5  3  6  3D7  MMV020746  13  13  5  3  3D7  MMV023367  6  6  4  5  Dd2  MMV024114  28  12  2  9  3D7  MMV026596  17  12  4  7  3D7  MMV027634  19  10  5  3  3D7  MMV028038  40  19  6  5  3D7  MMV029272  8  8  3  6  3D7  MMV665789  7  12  1  4  3D7  MMV665852  96  13  5  3  3D7  MMV665882  30  23  1  5  3D7  MMV665924  6  6  3  3  3D7  MMV665939  10  5  2  6  3D7  MMV668399  88  45  18  12  3D7  MMV673482  8  8  5  4  Dd2  NITD678  72 Table 2 . Summary of small variants organized by compound used to evolve resistance. Multiple clones from each drug selection were typically sequenced along with at least one isogenic parent clone. In some cases, multiple clones from a single flask were sequenced. These typically yielded virtually identical data, so identical variants from the same round of selection were not counted twice. Core variants are those excluded from subtelomeric regions. Codon changing variants are nonsynonymous coding, splice site, start lost or gained, disruptive insertion or deletion indels and frameshift indels. . There were notable hotspots on chromosome 1 around the lipid sterol symporter (PF3D7_0107500), on chromosome 3 around pfabcI3, and on chromosome 5 at pfmdr1. (B) CNVs in the known drug resistance gene pfmdr1. The heatmap displays clones grouped by compound and is brighter yellow in genes with higher coverage (>2.5X above the standard deviation). The scatter plot shows the correlation between higher CNV coverage and EC 50 fold change for clones resistant to all 3 compounds. Resistance shift was demonstrated in MMV665789 resistant clones (diamonds) compared to the sensitive parent (circles). Gel of the PCR products demonstrated that resistant clones contain the pfmdr1 CNV junction sequence, while a 3D7 control is missing the sequence. (C) CNVs in pfabcI3 are also associated with resistance to multiple compounds. Resistance shift was demonstrated in MMV029272 resistant clones (diamonds) compared to the sensitive parent (circles). Again, the CNV junction sequence was not found in the 3D7 Control DNA compared to clones resistant to MMV029272 (D) CNVs were found in pfatp2 in response to MMV007224 and MMV665882. :   Table of Contents  Materials and Methods  Figs. S1 to S6  Tables S7, S11 , S12, and S13 Additional Data (Captions for Tables S1-S6, S8-S10) Supplemental References 
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